Regulatory

Regulatory  ·  Weekly Digest 12 April to 18 April 2025
Hansoh Pharma announces NMPA has granted Breakthrough Therapy Designated drug for B7-H3-targeted antibody-drug conjugate HS-20093 for nsNSCLC

Weekly Digest – April 2025 Weekly Digest – April 2025 17 Apr 2025: Hansoh Pharma announces NMPA has granted Breakthrough Therapy Designated drug for B7-H3-targeted antibody-drug conjugate HS-20093 for nsNSCLC Hansoh Pharma announced that its B7-H3-targeted antibody-drug conjugate HS-20093 has […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest 12 April to 18 April 2025
SYS6041 (Antibody-Drug Conjugate) obtains clinical trial approval in the U.S.

Weekly Digest – April 2025 Weekly Digest – April 2025 14 Apr 2025: SYS6041 (Antibody-Drug Conjugate) obtains clinical trial approval in the U.S. CSPC Pharmaceutical Group received FDA approval to begin clinical trials in the U.S. for SYS6041, an antibody-drug […]

by Sandhya Ramalingam

Continue Reading